Date of SOH Approval: 26 August 2022 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of Second Booster of COVID-19 vaccines continue reading : Second Booster of COVID-19 Vaccines for the Prevention of COVID-19 Among Individuals Aged 50 Years Old and Older and Individuals with Comorbidities Aged 18 to 49 Years Old
Rituximab for the Treatment of Non-Hodgkin’s Lymphoma
Date of publication: 29 July 2022 Approval of the Secretary of health: 31 August 2022 Link to the Evidence summary HTAC Recommendation preview:
Insulin glargine (100 IU/mL, 10 mL vial and 3 mL pre-filled pen) for Type 1 and Type 2 Diabetes Mellitus
Preliminary Recommendation for the Inclusion of Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus in the PNF Link to the Evidence Summary: Evidence Summary on insulin glargine and detemir for type 1 and type 2 diabetes mellitus Link to appeals form here: https://hta.doh.gov.ph/topic-nomination/ (stakeholders may submit appeals to hta@doh.gov.ph until 11 August 2022.) Document Preview:
Lapatinib in the Treatment of HER2-Positive Breast Cancer Patients
Date of publication: May 31, 2021 Evidence Summary: https://drive.google.com/file/d/1VH5tkZyZr9sGWERXk8eXOyIQno456ixT/view Advisory on non-inclusion in PNF: https://drive.google.com/file/d/19PKRWWZ70bKUJBBuKyXnUjCtK01tzEgL/view (Proponents may submit appeals to hta@doh.gov.ph until 14 June 2021.) HTAC Recommendation Review: